Department of Food and Nutrition, Yonsei University, Seoul 03722, Korea.
Department of Food and Nutrition, Sookmyung Women's University, Seoul 04310, Korea.
Asian Pac J Cancer Prev. 2022 Feb 1;23(2):485-494. doi: 10.31557/APJCP.2022.23.2.485.
Gastrointestinal (GI) cancer patients often experience severe malnutrition during cancer therapies due to gastrointestinal dysfunctions including poor digestion and absorption as well as tumor-associated anorexia. In this study, we performed a randomized clinical trial to determine the efficacy of oral nutrition supplement (ONS) enriched with omega-3 fatty acids on nutritional status, quality of life (QOL), and pro-inflammatory indices.
Patients diagnosed with GI cancers were recruited and screened for eligibility. A total of 58 patients were randomly allocated to either the control group (n=27) or the experimental group (n=31). The intervention group received 200 ml ONS twice a day while the control group received routine care. Anthropometrics, Patient-Generated Subjective Global Assessment (PG-SGA) score, QOL score and nutrient intake data were collected at baseline, week 4 and week 8. Blood was drawn for biochemical assessments. Nine patients from each group dropped out of the study Forty patients (18 control patients and 22 intervention patients) completed the study.
This study showed that ONS intervention improved PG-SGA scores in the intervention group (p<0.01). Scores of physical functioning score and role functioning were declined only in the control group and the difference between week 8 and baseline for role functioning was significant (p<0.001). Fatigue score was steadily decreased in the experiment group, and the differences between week 8 and baseline was significant between two groups (p<0.02). However, no statistically significant improvement in biochemical markers of nutritional status and pro-inflammatory cytokine concentrations were found. These results suggests that ONS intervention for 8 weeks improves PG-SGA scores and QOL scores in patients undergoing cancer therapy.
癌症治疗期间，胃肠道（GI）癌症患者常因胃肠道功能障碍（包括消化不良和吸收不良以及肿瘤相关性厌食）而出现严重营养不良。本研究旨在进行一项随机临床试验，以确定富含ω-3 脂肪酸的口服营养补充剂（ONS）对营养状况、生活质量（QOL）和促炎指标的疗效。
招募并筛选诊断为 GI 癌症的患者，以确定其是否符合纳入标准。共有 58 名患者被随机分配至对照组（n=27）或实验组（n=31）。干预组每天接受 200 ml ONS 两次，对照组接受常规护理。在基线、第 4 周和第 8 周收集人体测量学、患者生成的主观整体评估（PG-SGA）评分、QOL 评分和营养素摄入量数据。采集血液进行生化评估。每组各有 9 名患者退出研究，共有 40 名患者（18 名对照组患者和 22 名干预组患者）完成了研究。
本研究表明，ONS 干预可改善干预组的 PG-SGA 评分（p<0.01）。身体功能评分和角色功能评分仅在对照组中下降，且角色功能评分在第 8 周和基线之间的差异具有统计学意义（p<0.001）。实验组的疲劳评分持续下降，两组间第 8 周和基线之间的差异具有统计学意义（p<0.02）。然而，我们未发现营养状态和促炎细胞因子浓度的生化标志物有统计学显著改善。这些结果表明，ONS 干预 8 周可改善癌症治疗患者的 PG-SGA 评分和 QOL 评分。
